Joern Schattenberg

Appearances

SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
Date
May 21, 2024
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
Presenter
Naim Alkhouri
Speakers
Mandy Fraessdorf
Guy Neff
Joern Schattenberg
Mazen Noureddin
Houston Methodist Hospital
Eric Lawitz
Quentin Anstee
Elisabetta Bugianesi
Samina Ajaz Hussain
Philip Newsome